GlassScriptPhysician profile
Karin I Harp
NPI 1518923374
$13,781.22
in general payments reported to CMS, 2019-2025
37 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $1,141 · 2021: $2,982 · 2022: $1,693 · 2023: $2,770 · 2024: $2,769 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,012 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,011.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,851.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,963.96 | 2021-2025 | |
| Merz North America, INC. | $1,939.21 | 2019-2024 | Xeomin |
| Allergan, INC. | $1,532.35 | 2019-2023 | |
| Strata Skin Sciences, INC. | $989.54 | 2019-2024 | Xtrac |
| Janssen Biotech, INC. | $752.14 | 2020-2024 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $734.71 | 2022-2025 | |
| Galderma Laboratories, L.P. | $683.16 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $539.47 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $427.37 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $388.99 | 2019-2025 | Adbry |
| Pfizer INC. | $364.18 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $294.94 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $276.75 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Incyte Corporation | $240.01 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $217.07 | 2019-2024 | Taltz, Olumiant, Zepbound |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $175.71 | 2019-2023 | |
| Amgen INC. | $169.67 | 2022-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $141.72 | 2023-2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $133.60 | 2020-2021 | |
| Biofrontera INC. | $91.35 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Solta Medical, A Division of Bausch Health US, LLC | $87.31 | 2019-2022 | |
| Dermavant Sciences, INC. | $77.76 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $72.72 | 2020-2021 | |
| Journey Medical Corporation | $66.04 | 2019-2022 | |
| Genentech USA, INC. | $60.58 | 2019-2021 | |
| Almirall LLC | $51.13 | 2020-2023 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $43.60 | 2022-2023 | Valchlor |
| Organogenesis INC. | $38.56 | 2024 | Cygnus Dual |
| Botanix Sb INC | $36.90 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $35.22 | 2019-2020 | |
| Epi Health, LLC | $30.53 | 2019-2020 | |
| Ucb, INC. | $29.34 | 2024 | Bimzelx |
| Encore Dermatology INC. | $24.21 | 2020 | |
| Sandoz INC. | $22.74 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.64 | 2019 | |
| Aclaris Therapeutics, INC. | $15.93 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.11 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.